Iseki Kunitoshi, Moromizato Takuhiro, Iseki Chiho, Nakamura Kei, Nakamura Hiroshi
Nakamura Clinic, Urasoe, Okinawa, Japan.
Okinawa Heart and Renal Association, Okinawa, Japan.
Clin Exp Nephrol. 2025 Apr;29(4):485-491. doi: 10.1007/s10157-024-02604-5. Epub 2024 Dec 15.
We observed lower risk of all-cause mortally among continuous positive airway pressure (CPAP) users compared to those non-users using a large polysomnography (PSG) registry. However, the effect of CPAP on mortality risk has not been examined in dialysis patents.
We studied 9841 patients with PSG performed from September 1990 to 2010 in Nakamura clinic, Okinawa. Among them, we found 195 dialysis patients: 16 (1.0%) dialysis patients with apnea hypopnea index (AHI) < 5/hour in 1665 subjects and 179 (2.2%) in 8176 obstructive sleep apnea (OSA) patients. CPAP users were defined as patients who had been on CPAP for more than one month. Patients qualified and eligible for CPAP but refused were assigned as CPAP non-users. The median observation was 6.6 years. Mortality rates were compared between CPAP users and non-users using multivariate logistic analysis adjusted for age, sex, body mass index (BMI), AHI and medical history.
Among OSA dialysis patients (men 127, women 37), 116 (2.6%) were CPAP users and 48 (2.3%) were CPAP non-users. The number of deaths was 52 (29 CPAP users and 23 (CPAP non-users) during follow-up. The death rate was 25.0% for CPAP users and 47.9% for non-users. CPAP users showed better survival; hazard ratio (HR) 0.47 and 95% confidence interval (CI) of 0.27-0.81 (P = 0.007).
Dialysis patients with OSA showed better survival rates with the use of CPAP. Screening for OSA is recommended if patients complain of sleep problems, such as insomnia, daytime sleepiness, headache, and fatigue.
通过一项大型多导睡眠图(PSG)登记研究,我们观察到持续气道正压通气(CPAP)使用者的全因死亡风险低于未使用者。然而,CPAP对透析患者死亡风险的影响尚未得到研究。
我们研究了1990年9月至2010年在冲绳中村诊所进行PSG检查的9841例患者。其中,我们发现195例透析患者:在1665名受试者中有16例(1.0%)透析患者的呼吸暂停低通气指数(AHI)<5次/小时,在8176例阻塞性睡眠呼吸暂停(OSA)患者中有179例(2.2%)。CPAP使用者定义为使用CPAP超过一个月的患者。符合CPAP使用条件但拒绝使用的患者被指定为CPAP非使用者。中位观察期为6.6年。使用多因素逻辑分析比较CPAP使用者和非使用者的死亡率,并对年龄、性别、体重指数(BMI)、AHI和病史进行调整。
在OSA透析患者中(男性127例,女性37例),116例(2.6%)为CPAP使用者,48例(2.3%)为CPAP非使用者。随访期间死亡人数为52例(29例CPAP使用者和23例CPAP非使用者)。CPAP使用者的死亡率为25.0%,非使用者为47.9%。CPAP使用者的生存率更高;风险比(HR)为0.47,95%置信区间(CI)为0.27 - 0.81(P = 0.007)。
OSA透析患者使用CPAP可提高生存率。如果患者主诉睡眠问题,如失眠、日间嗜睡、头痛和疲劳,建议对其进行OSA筛查。